Population pharmacokinetics of amodiaquine and desethylamodiaquine in pediatric patients with uncomplicated falciparum malaria
- 187 Downloads
The study aimed to characterize the population pharmacokinetics of amodiaquine (AQ) and its major metabolite N-desethylamodiaquine (N-DEAQ), and to assess the correlation between exposure to N-DEAQ and treatment outcome. Blood samples from children in two studies in Zanzibar and one in Papua New Guinea were included in the pharmacokinetic analysis (n = 86). The children had been treated with AQ in combination with artesunate or sulphadoxine-pyrimethamine. The population pharmacokinetics of AQ and N-DEAQ were modeled using the non-linear mixed effects approach as implemented in NONMEM. Bayesian post-hoc estimates of individual pharmacokinetic parameters were used to generate individual profiles of N-DEAQ exposure. The correlation between N-DEAQ exposure and effect was studied in 212 patients and modeled with logistic regression in NONMEM. The pharmacokinetics of AQ and N-DEAQ were best described by two parallel two-compartment models with a central and a peripheral compartment for each compound. The systemic exposure to AQ was low in comparison to N-DEAQ. The t 1/2λ of N-DEAQ ranged from 3 days to 12 days. There was a statistically significant, yet weak, association between N-DEAQ concentration on day 7 and treatment outcome. The age-based dosing schedule currently recommended in Zanzibar appeared to result in inadequate exposure to N-DEAQ in many patients.
KeywordsAmodiaquine Desethylamodiaquine Malaria Child Population pharmacokinetic/pharmacodynamic modeling
Unable to display preview. Download preview PDF.
- 7.Laurent F, Saivin S, Chretien P, Magnaval JF, Peyron F, Sqalli A, Tufenkji AE, Coulais Y, Baba H and Campistron G (1993). Pharmacokinetic and pharmacodynamic study of amodiaquine and its two metabolites after a single oral dose in human volunteers. Arzneimittelforschung 43(5): 612–616 PubMedGoogle Scholar
- 11.Aubouy A, Bakary M, Keundjian A, Mbomat B, Makita JR, Migot-Nabias F, Cot M, Le Bras J and Deloron P (2003). Combination of drug level measurement and parasite genotyping data for improved assessment of amodiaquine and sulfadoxine-pyrimethamine efficacies in treating Plasmodium falciparum malaria in Gabonese children. Antimicrob Agents Chemother 47(1): 231–237 PubMedCrossRefGoogle Scholar
- 12.Hombhanje FW, Hwaihwanje I, Tsukahara T, Saruwatari J, Nakagawa M, Osawa H, Paniu MM, Takahashi N, Lum JK, Aumora B, Masta A, Sapuri M, Kobayakawa T, Kaneko A and Ishizaki T (2005). The disposition of oral amodiaquine in Papua New Guinean children with falciparum malaria. Br J Clin Pharmacol 59(3): 298–301 PubMedCrossRefGoogle Scholar
- 18.Holford N (2005) A degenerative predictive check. In: 14th P.A.G.E. Meeting. PamplonaGoogle Scholar
- 19.Montgomery DC, Peck EA and Vining GG (2001). Introduction to linear regression analysis. Wiley, Chichester, New York Google Scholar
- 20.Holford N (2007) Wings for NONMEM Version 600. Accessed: April 2007Google Scholar
- 23.Rowland M and Tozer TN (1995). Clinical pharmacokinetics: concepts and applications. Williams and Wilkins, USA Google Scholar
- 24.Guidelines for the treatment of malaria/ World Health Organization 2006Google Scholar
- 25.Taylor WR, Terlouw DJ, Olliaro PL, White NJ, Brasseur P and ter Kuile FO (2006). Use of weight-for-age-data to optimize tablet strength and dosing regimens for a new fixed-dose artesunate-amodiaquine combination for treating falciparum malaria. Bull World Health Organ 84(12): 956–964 PubMedCrossRefGoogle Scholar
- 26.Martensson A, Stromberg J, Sisowath C, Msellem MI, Gil JP, Montgomery SM, Olliaro P, Ali AS and Bjorkman A (2005). Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania. Clin Infect Dis 41(8): 1079–1086 PubMedCrossRefGoogle Scholar